(1) S100 expression or activity may serve as a predictive biomarker for response to chemotherapy, immunotherapy, or targeted treatments in BC, and should be evaluated in retrospective cohorts and prospective trials (63, 64). The gene discussed is S100A1; the disease is breast cancer.